Hepatotoxicity of Antibody-drug Conjugates
10.3969/j.issn.1008-7125.2024.05.001
- VernacularTitle:抗体偶联药物的肝毒性研究进展
- Author:
Yinuo DONG
1
;
Yang ZHI
1
;
Xiaoyun LI
1
;
Xiaohong LEI
1
;
Jieting TANG
1
;
Yimin MAO
1
Author Information
1. 上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所上海市脂肪性肝病诊治研究中心(200001)
- Publication Type:Journal Article
- Keywords:
Antibody-Drug Conjugates;
Hepatotoxicity;
Cancer;
Clinical Trials
- From:
Chinese Journal of Gastroenterology
2024;29(5):257-260
- CountryChina
- Language:Chinese
-
Abstract:
Cancer has become a major life-threatening disease globally.In recent years,precision therapy for cancer has gradually emerged,and significant success has been achieved with targeted therapies,immune checkpoint inhibitors,and the newly emerging antibody-drug conjugates(ADC).The development of ADC has been rapid,with up to 15 ADC drugs currently approved worldwide.However,the hepatotoxicity of ADC has gained increasing attention,with reports of fatal hepatotoxic events.In this article,we briefly reviewed the ADC approved globally,summarized the liver-related adverse events and hepatotoxic manifestations reported in current clinical trials of ADC,and compiled research on possible hepatotoxicity mechanisms.Our aim is to assist clinicians in understanding and managing the hepatotoxicity characteristics of ADC,enabling timely identification of patients at risk of hepatotoxicity and implementing effective measures to manage these risks,thus reducing and preventing serious adverse events.
